The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical indicators show weakening trends, including a recent break of trendline support, suggesting a possible 10% price correction to around $97 by October. Seasonal factors are also unfavorable in September and October, although long-term growth drivers like artificial intelligence remain promising. Investors should be cautious of near-term risks despite the ETF's strong summer performance.
In 2026, JPMorgan's Nasdaq-focused ETF (JEPQ) has delivered significantly higher monthly income distributions than its S&P 500-based sibling (JEPI), driven by the greater volatility and option premiums of the tech-heavy Nasdaq index. JEPI offers broa...
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Johnson & Johnson announced new pivotal Phase 3 clinical data for CAPLYTA (lumateperone) in treating bipolar mania, alongside additional findings in bipolar depression and major depressive disorder. The data, presented at the 2026 Psych Congress, hig...
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Pr...
